Abstract
Dengue envelope (E) protein is a dominant antigen for vaccine development and E-based vaccines have shown partial or full protection against live-virus challenge in non-human primates. Generally, T cell responses can be investigated with peptides. However, hundreds of over-lapping peptides need to be synthesized to cover the whole sequence of a protein, which brings the cost up to a much higher level than purchasing a protein. We have developed an enzyme-linked immunospot (ELISpot) assay that uses intact E proteins instead of peptides for assessing IFN-gamma (IFN-γ) responses. The assay relies on professional antigen presenting cells, dendritic cells, to process and present the E proteins to stimulate T cells.
Peripheral blood mononuclear cells (PBMCs) from dengue-exposed and naïve subjects were selected for the assay development. IFN-γ production ranged from 53 to 513 spot forming units (SFUs) and 0–45 SFUs per million PBMCs in dengue-exposed and naive subject groups, respectively. The assay allowed quantification of E-specific IFN-γ secreting memory T cells in subjects 9 years after exposure to a live-attenuated virus vaccine and live-virus challenge. Our results suggest that the dendritic cell-based IFN-γ assay is a useful tool for assessing immunological memory for clinical research.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Mukhopadhyay S, Kuhn RJ, Rossmann MG (2005) A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3(1):13–22. https://doi.org/10.1038/nrmicro1067
Guzman MG, Harris E (2015) Dengue. Lancet 385(9966):453–465. https://doi.org/10.1016/S0140-6736(14)60572-9
Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI (2013) The global distribution and burden of dengue. Nature 496(7446):504–507. https://doi.org/10.1038/nature12060
Simmons CP (2015) A candidate dengue vaccine walks a tightrope. N Engl J Med 373(13):1263–1264. https://doi.org/10.1056/NEJMe1509442
Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A, Group CYDS (2014) Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384(9951):1358–1365. https://doi.org/10.1016/S0140-6736(14)61060-6
Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramirez JO, Carrasquilla G, Rey LC, Dietze R, Luz K, Rivas E, Miranda Montoya MC, Cortes Supelano M, Zambrano B, Langevin E, Boaz M, Tornieporth N, Saville M, Noriega F, Group CYDS (2015) Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372(2):113–123. https://doi.org/10.1056/NEJMoa1411037
Nedjadi T, El-Kafrawy S, Sohrab SS, Despres P, Damanhouri G, Azhar E (2015) Tackling dengue fever: Current status and challenges. Virol J 12:212. https://doi.org/10.1186/s12985-015-0444-8
Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM (1997) Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3(8):866–871
Wahala WM, Silva AM (2011) The human antibody response to dengue virus infection. Virus 3(12):2374–2395. https://doi.org/10.3390/v3122374
Sun P, Beckett C, Danko J, Burgess T, Liang Z, Kochel T, Porter K (2011) A dendritic cell-based assay for measuring memory T cells specific to dengue envelope proteins in human peripheral blood. J Virol Methods 173(2):175–181. https://doi.org/10.1016/j.jviromet.2011.01.023
Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J (2012) Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380(9853):1559–1567. https://doi.org/10.1016/S0140-6736(12)61428-7
Sierra B, Garcia G, Perez AB, Morier L, Rodriguez R, Alvarez M, Guzman MG (2002) Long-term memory cellular immune response to dengue virus after a natural primary infection. Int J Infect Dis 6(2):125–128
Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, Sawasdivorn S, Duangchinda T, Dong T, Rowland-Jones S, Yenchitsomanus PT, McMichael A, Malasit P, Screaton G (2003) Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 9(7):921–927. https://doi.org/10.1038/nm887
Kurane I, Meager A, Ennis FA (1989) Dengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon gamma production, and cytotoxic activity. J Exp Med 170(3):763–775
Disclaimer
The views expressed in this chapter are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, the U.S. Government or the Henry Jackson Foundation (HJF). MS is an employee of the U.S. Government and PS is a HJF government contract employee. Title 17 U.S.C. article 105 provides that “Copyright protection under this title is not available for any work of the United States Government.” Title 17 U. S.C. article 101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person’s official duties. The study protocol was approved by the Naval Medical Research Center Institutional Review Board in compliance with all applicable federal regulations governing the protection of human subjects.
Financial SupportThis work was funded by a grant from the Military Infectious Disease Research Program (MIDRP), U.S. Army Medical Research and Materiel Command, Fort Detrick, MD, work unit number A0311.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Sun, P., Simmons, M. (2018). Dendritic Cell-Based ELISpot Assay for Assessing T-Cell IFN-γ Responses in Human Peripheral Blood Mononuclear Cells to Dengue Envelope Proteins. In: Kalyuzhny, A. (eds) Handbook of ELISPOT . Methods in Molecular Biology, vol 1808. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8567-8_17
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8567-8_17
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8566-1
Online ISBN: 978-1-4939-8567-8
eBook Packages: Springer Protocols